U.S. market Closed. Opens in 5 hours 54 minutes

MNK | Mallinckrodt plc Stock Overview

(Stock Exchange: AMEX)
Day's Range 0.3000 - 0.4102
52 Week Range 0.3000 - 16.00
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 543,145
Average Volume 3,710,535
Shares Outstanding 13,289,200
Market Cap 4,520,986
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2022-06-21
Valuation
Profitability
Growth
Health
P/E Ratio -0.44
Forward P/E Ratio N/A
EPS -0.78
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 2,673
Country Ireland
Website MNK
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which includes innovative specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States.
*Chart delayed
Analyzing fundamentals for MNK we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see MNK Fundamentals page.

Watching at MNK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on MNK Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙